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Summary A 31-year-old man suddenly collapsed at work. His colleagues witnessed the event,
applied basic life support, and called for an ambulance. After the ambulance arrived, the initial
rhythm was conﬁrmed as ventricular ﬁbrillation (VF) and he was deﬁbrillated with an automated
external deﬁbrillator. Spontaneous circulation was regained at 8min after collapse. He was
thought to be a good candidate for therapeutic hypothermia because he was comatose and
had survived outside hospital VF cardiac arrest due to cardiac etiology. However, he was taking
immunosuppressive drugs after undergoing a kidney transplant. We obtained written, informed
consent from the patient’s family to start therapeutic hypothermia at 33.5—34.5 ◦C for 48 h,
although he was at high risk for such induction. Serious complications and neurological deﬁcits
did not develop and the patient was referred to another hospital on day 42 for implantation
with a cardioverter deﬁbrillator.
Car© 2009 Japanese College of∗ Corresponding author. Tel.: +81 072 683 9911;
fax: +81 072 683 6111.
E-mail address: zushi136@osaka-mishima.jp (R. Zushi).
I
R
2
t
r
H
w
1878-5409/$ — see front matter © 2009 Japanese College of Cardiology.
doi:10.1016/j.jccase.2009.12.001diology. Published by Elsevier Ireland Ltd. All rights reserved.
ntroduction
andomized controlled trials in Europe and Australia during
002 revealed that therapeutic mild hypothermia improves
he neurological outcomes of patients with ventricular ﬁb-
illation (VF) cardiac arrest due to cardiac causes [1,2].
owever, therapeutic mild hypothermia was also associated
ith a relatively high incidence of infectious diseases such as
Published by Elsevier Ireland Ltd. All rights reserved.
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epsis or pneumonia [1,2]. Therefore, immunocompromised
osts can be at high risk in the induction of therapeutic mild
ypothermia. We describe a patient on immunosuppressive
rugs after renal transplantation who underwent therapeu-
ic mild hypothermia for prolonged coma after VF and who
as revived without neurological deﬁcits and serious com-
lications.
ase report
31-year-old man suddenly collapsed at work. His col-
eagues witnessed the event, applied basic life support,
nd called an ambulance. At the time the ambulance
rrived, VF was detected as the initial rhythm and he
as deﬁbrillated with an automated external deﬁbrilla-
or. He regained spontaneous circulation at 8min after
ollapse and was transported to Osaka Mishima Emer-
ency and Critical Care Center. Upon admission, his vital
igns were as follows: blood pressure 102/77mmHg, reg-
lar pulse rate of 102 beats, and Glasgow coma scale 3.
eart sounds were normal but respiratory sounds were
oarse on all lung ﬁelds. A chest X-ray showed a butter-
y shadow. Transthoracic echocardiography demonstrated
nly slightly impaired left ventricular contractility and coro-
ary angiography was normal. We diagnosed idiopathic VF
omplicated with pulmonary congestion. We considered
im as a good candidate for therapeutic hypothermia but
e had undergone a kidney transplant to treat chronic
enal failure due to a congenital urinary obstruction so he
as taking cyclosporine 75mg/day, mycophenolate mofetil
000mg/day, and methyl-prednisolone 4mg/day. Consulta-
ion with his family physician indicated that therapeutic
ypothermia was an option under continued cyclosporine
nd methyl-prednisolone based on the general consensus
egarding invasive therapy for renal transplant patients. The
dvantages and disadvantages of therapeutic hypothermia
ere explained to his family, who then provided written,
nformed consent to the procedure. Thus, the elapsed time
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Figure 1 Clinical course of body temperatuR. Zushi et al.
etween collapse and the start of therapeutic hypothermia
as 224min, which was 210min from admission. The tar-
et body temperature as urine temperature and duration of
ooling were 33.5—34.5 ◦C and 48 h, respectively. Body tem-
erature was decreased and maintained using iced saline
astric lavage and 1 or 2 cooling blankets, and the target
emperature was reached at 806min after admission and
20min after collapse (Fig. 1). The 48-h cooling period was
ompleted on day 3, and then the patient was warmed at
rate of 1 ◦C per day (Fig. 1). Body temperature increased
eyond 38 ◦C at day 5 after warming was completed despite
reventive ampicillin (2 g/day) being administered for 3 days
ince day 1 (Fig. 1). We considered this as rebound hyper-
hermia because an infectious focus was absent although his
hite blood cell count (WBC) and C-reactive protein (CRP)
evels were slightly elevated. Thereafter, his body temper-
ture fell naturally to the normal range (Fig. 2). Sedation
as discontinued on day 6. Phenytoin was administered for
eizure on day 7 and he recovered consciousness and could
nswer questions on the same day.
Immunosuppressive drugs included 120mg/day of
yclosporine delivered transvenously on day 1 and the
ose was decreased to 60mg/day on day 5 as blood levels
ncreased to 540 ng/ml (therapeutic range: 150—300 ng/ml)
Fig. 2). Cyclosporine was returned to the standard dose
f 75mg/day p.o. and 1000mg/day of mycophenolate
ofetil was started on day 6 (Fig. 2). Methyl-prednisolone
500mg) administered as steroid cover on day 1 was
educed to the standard dose of 4mg on day 6 (Fig. 2).
e also administered 20mg/day of prednisolone from days
to 8 and 10mg/day on days 9 and 10 (Fig. 2). Although
BC and CRP level had elevated from day 7 to 10 and his
ody temperature went over 38 ◦C at day 7 immediately
fter oral immunosuppressive drugs were started, he was
n a good general condition without local symptoms of
nfectious disease and his body temperature immediately
ent down to 37.5 ◦C at day 8, so we continued immuno-
uppressive drugs without administration of antibiotics
Fig. 2). Thereafter, the patient remained free of serious
re during therapeutic mild hypothermia.
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fFigure 2 Clinical course of laboratory ﬁndings. WBC, white b
creatinine; K, potassium; Cs, cyclosporine; MMF, mycophenolate
infection and decreased renal function (Fig. 1). Moreover,
cranial magnetic resonance imaging revealed no abnormal
intensity. He was referred to another hospital on day 42
for implantation with a cardioverter deﬁbrillator. Stress
electrocardiogram and gallium scintigraphy demonstrated
normal ﬁndings, but electrophysiological study was refused.
Therefore, a cardioverter deﬁbrillator was implanted with
ﬁnal diagnosis of the idiopathic ventricular ﬁbrillation.
Discussion
Various adverse events are associated with therapeutic mild
hypothermia, and among them, pneumonia and sepsis are
the most frequent and serious [1,2]. Patients on immuno-
suppressive drugs after renal transplantation are presumed
to be at high risk from therapeutic mild hypothermia. In fact,
one feasibility study of mild hypothermia excluded patients
who had undergone renal transplantation [3]. Therefore,
our effort to induce mild therapeutic hypothermia for a
patient on immunosuppressive drugs presented a signiﬁcant
challenge. We adopted 48 h as the cooling period, 1 ◦C per
day as the warming rate, and 33.5—34.5 ◦C as the target
temperature. Others [4,5] have demonstrated that cooling
periods beyond 24 h increase the incidence of complications
and current guidelines for therapeutic hypothermia recom-
mend cooling periods of 12—24 h [6]. The warming period
should also be modiﬁed from 1 ◦C/day to beyond 8 or 12 h
according to two randomized controlled trials [1,2]. More-
over, given that the elapsed time from cardiac arrest to
return of spontaneous circulation was relatively short and
immunosuppressive treatment had been taken in this case, a
o
h
t
tcell count; neutro, neutrophils; CRP, C-reactive protein; CRE,
fetil; Met-PSL, methyl-prednisolone; PSL, prednisolone.
ooling time of 12—24 h might be sufﬁcient and safe. That is,
hortening the cooling and warming periods might be advan-
ageous. However, an experimental study [7] revealed the
fﬁcacy of cooling period beyond 24 h particularly in cases
here induction of therapeutic hypothermia was delayed, so
8 h of cooling might be warranted in this case because the
ime from collapse to initiation of therapeutic hypothermia
as as long as 224min. The ideal cooling duration remains
nclear, much less in compromised hosts, so we cannot con-
lude an adequate cooling duration at present.
The body temperature of our patient brieﬂy fell below
he target temperature, which should have been more
trictly managed, since such overrun is related to the inci-
ence of complications [4,5]. The Arctic Sun (a surface
ooling system) [8], or endovascular [9] or nasopharyngeal
10] cooling systems can be used to strictly control body
emperature. Among these systems, the Arctic Sun sys-
em should have been considered for our patient because
xtracorporeal circulation or endovascular cooling might
acilitate infection through blood access and the nasopha-
yngeal cooling system is not widely available in clinical
ettings.
Only cyclosporine and methyl-prednisolone were con-
inued for immunosuppression during the acute phase and
ycophenolate mofetil was restarted at day 6 accord-
ng to the general consensus regarding invasive therapy
or patients after renal transplantation. Adequate types
r doses of immunosuppressants during therapeutic mild
ypothermia remain unknown and more patients undergoing
his procedure will need to be studied.
Another concern is the inﬂuence of hypothermia upon
he function of the transplanted kidney. Hypothermia is rel-
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tively protective towards various organs by reducing their
etabolic rates [11]. Thus therapeutic mild hypothermia
s unlikely to negatively inﬂuence the transplanted kid-
ey. However, further investigation is required to prove this
ssertion.
onclusion
e described the case of a 31-year-old man on immunosup-
ressive drugs after renal transplantation who underwent
8 h of mild therapeutic hypothermia for prolonged
oma after out-of-hospital cardiac arrest. He survived
ithout neurological deﬁcits and serious complications.
ypothermic therapy might be safe for patients on
mmunosuppressive drugs, although further investigation
nd experience are warranted.
cknowledgment
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